Novo Nordisk: The First Long-Acting Coagulation Factor VIII Nuwiq Officially Launches in Mainland China

K-LinePoet · 2026-02-11T16:10:04+00:00

Novo Nordisk recently announced the official上市 of its long-acting recombinant coagulation factor VIII, Nuwiq, in mainland China, and it has been included in the national medical insurance catalog. This marks the filling of the gap in long-term treatment options for hemophilia A in China and improves medication accessibility for patients. Since its approval in the United States in 2019, Nuwiq has demonstrated good efficacy and safety, providing a new option for Chinese patients with hemophilia A.

K-LinePoet

2026-02-11 16:10:04

Abstract generation in progress

Recently, Novo Nordisk announced that injected pegylated recombinant coagulation factor VIII (brand name: Nuwiq) has been officially launched in mainland China. Nuwiq is currently the only approved long-acting recombinant coagulation factor VIII in China and has been successfully included in the new national medical insurance catalog. The comprehensive market launch of Nuwiq in mainland China fills the gap in long-acting treatment for hemophilia A, further improving patient access to medication and bringing Chinese hemophilia A patients into a new treatment era.

The announcement mentioned that hemophilia is an X-linked recessive hereditary bleeding disorder, which can be divided into hemophilia A and hemophilia B. Hemophilia A is characterized by a deficiency of coagulation factor VIII (F VIII), accounting for about 80%-85% of all hemophilia cases. Patients require lifelong treatment; without timely therapy, it can lead to disability, and in severe cases, even threaten life. With continuous advances in treatment methods, studies show that more patients are expecting long-acting coagulation factors to reduce injection frequency.

Since its approval in the United States in 2019, Nuwiq has accumulated extensive data on efficacy and safety for bleeding prevention and treatment worldwide. In a multicenter trial in Chinese hemophilia A patients, Pathfinder105 results showed that among patients receiving prophylactic treatment, the median annualized bleeding rate (ABR) was 0.00, with 69.4% of patients experiencing no bleeding episodes, and the hemostatic success rate for bleeding episodes was 94.8%. This provides an efficient and convenient treatment option for Chinese hemophilia A patients.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.